Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Preliminary observations on APOE epsilon 4 allele and progression of disability in multiple sclerosis
Autore:
Chapman, J; Sylantiev, C; Nisipeanu, P; Korczyn, AD;
Indirizzi:
Tel Aviv Med Ctr, Dept Neurol, Tel Aviv, Israel Tel Aviv Med Ctr Tel Aviv Israel Med Ctr, Dept Neurol, Tel Aviv, Israel Tel Aviv Med Ctr, Neuroimmunol Clin, Tel Aviv, Israel Tel Aviv Med Ctr Tel Aviv Israel r, Neuroimmunol Clin, Tel Aviv, Israel
Titolo Testata:
ARCHIVES OF NEUROLOGY
fascicolo: 12, volume: 56, anno: 1999,
pagine: 1484 - 1487
SICI:
0003-9942(199912)56:12<1484:POOAE4>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; NERVE; ONSET; DEMYELINATION; REMYELINATION; EXPRESSION; ASTROCYTES; SECRETION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Korczyn, AD Tel Aviv Univ, Sieratzki Chair Neurol, IL-69978 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-69978 9978 Tel Aviv, Israel
Citazione:
J. Chapman et al., "Preliminary observations on APOE epsilon 4 allele and progression of disability in multiple sclerosis", ARCH NEUROL, 56(12), 1999, pp. 1484-1487

Abstract

Background: Apolipoprotein E expression is increased in regenerating neural tissue and the APOE epsilon 4 allele is associated with impaired neuronalrepair. Since repair is essential for the restoration of central nervous system function following multiple sclerosis (MS) relapses, APOE genotype may influence clinical progression of the disease. Objective: To examine the association of the APOE genotype with disease susceptibility and progression in MS. Patients and Methods: APOE genotyping was determined by polymerase chain reaction and restriction enzyme digestion in 47 patients with MS who had been followed up every 3 months for 2 years as part of an open-label clinical trial with glatiramer acetate. The Expanded Disability Status Scale (EDSS) was used to assess clinical progression. Results: Nine patients were heterozygous and 1 patient was homozygous for the APOE epsilon 4 allele, for a frequency of 12% (11/94), which is similarto that of the general Israeli population. The APOE epsilon 4 carriers hada mean +/- SE EDSS score of 3.10 +/- 0.45 at entry, which was not significantly different from the remaining 37 patients (2.62 +/- 0.25). During the observation period, the EDSS score of the APOE epsilon 4 carriers deteriorated to 4.00 +/- 0.63 while the other patients remained stable with an EDSS score of 2.74 +/-: 0.31. The interaction of genotype with disability over time was significant (P = .02 by repeated-measures analysis of variance). There were no differences in the number of relapses occurring in the 2 groups. Conclusions: These preliminary observations suggest that APOE genotype mayinfluence disease progression in MS. The APOE epsilon 4 allele was not associated with an increased risk of MS or relapses.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 19:18:30